| Allograft rejection |
2.42 |
0.00e+0 |
32/38 (84.21%) |
HLA-B;HLA-F;HLA-C;...
|
| p53 signaling pathway |
2.40 |
0.00e+0 |
63/73 (86.3%) |
CDKN1A;DDB2;SESN1;...
|
| Graft-versus-host disease |
2.39 |
0.00e+0 |
32/42 (76.19%) |
HLA-B;HLA-F;HLA-C;...
|
| Autoimmune thyroid disease |
2.38 |
0.00e+0 |
46/53 (86.79%) |
HLA-B;HLA-F;HLA-C;...
|
| Epstein-Barr virus infection |
2.31 |
0.00e+0 |
189/202 (93.56%) |
CDKN1A;HLA-B;DDB2;...
|
| Herpes simplex virus 1 infection |
2.31 |
0.00e+0 |
165/498 (33.13%) |
HLA-B;HLA-F;IRF9;...
|
| Type I diabetes mellitus |
2.28 |
0.00e+0 |
38/43 (88.37%) |
HLA-B;HLA-F;HLA-C;...
|
| Cytosolic DNA-sensing pathway |
2.18 |
0.00e+0 |
52/63 (82.54%) |
IL1B;POLR2H;POLR2L;...
|
| Influenza A |
2.17 |
0.00e+0 |
156/172 (90.7%) |
MX1;IRF9;IL1B;...
|
| Viral myocarditis |
2.09 |
0.00e+0 |
53/60 (88.33%) |
CXADR;HLA-B;HLA-F;...
|
| Measles |
2.04 |
0.00e+0 |
133/139 (95.68%) |
MX1;IRF9;TP53;...
|
| Toll-like receptor signaling pathway |
1.98 |
8.30e-4 |
94/104 (90.38%) |
IL1B;CASP8;CXCL8;...
|
| Lysosome |
1.96 |
1.53e-3 |
115/128 (89.84%) |
FUCA1;NEU1;ASAH1;...
|
| Legionellosis |
1.95 |
1.42e-3 |
51/57 (89.47%) |
IL1B;CASP8;CXCL8;...
|
| Apoptosis |
1.93 |
1.99e-3 |
126/168 (75%) |
GADD45A;TP53;FAS;...
|
| NF-kappa B signaling pathway |
1.93 |
1.87e-3 |
90/104 (86.54%) |
RELB;GADD45A;IL1B;...
|
| Rheumatoid arthritis |
1.92 |
1.76e-3 |
78/93 (83.87%) |
IL1B;HLA-DQA1;CXCL8;...
|
| Antigen processing and presentation |
1.91 |
1.66e-3 |
60/78 (76.92%) |
HLA-B;IFI30;HLA-F;...
|
| Pertussis |
1.91 |
1.57e-3 |
64/76 (84.21%) |
IL1B;CXCL8;MYD88;...
|
| Leishmaniasis |
1.90 |
1.49e-3 |
67/77 (87.01%) |
MARCKSL1;IL1B;HLA-DQA1;...
|
| Staphylococcus aureus infection |
1.90 |
1.90e-3 |
72/95 (75.79%) |
CFB;HLA-DQA1;KRT16;...
|
| Hepatitis C |
1.89 |
2.26e-3 |
139/157 (88.54%) |
CDKN1A;MX1;IFIT1;...
|
| Necroptosis |
1.88 |
2.60e-3 |
113/159 (71.07%) |
IRF9;IL1B;SLC25A4;...
|
| Tuberculosis |
1.83 |
3.73e-3 |
159/180 (88.33%) |
CLEC7A;IL1B;HLA-DQA1;...
|
| Taurine and hypotaurine metabolism |
1.79 |
5.58e-3 |
8/11 (72.73%) |
ADO;CSAD;GAD1
|
| Kaposi sarcoma-associated herpesvirus infection |
1.78 |
6.13e-3 |
172/193 (89.12%) |
CDKN1A;HLA-B;HLA-F;...
|
| Base excision repair |
1.78 |
5.90e-3 |
29/33 (87.88%) |
POLE3;FEN1;NEIL1;...
|
| Phagosome |
1.75 |
7.11e-3 |
118/152 (77.63%) |
HLA-B;CLEC7A;HLA-F;...
|
| Inflammatory bowel disease |
1.75 |
7.90e-3 |
58/65 (89.23%) |
IL1B;MAF;HLA-DQA1;...
|
| RIG-I-like receptor signaling pathway |
1.72 |
9.00e-3 |
64/70 (91.43%) |
ISG15;CASP8;CXCL8;...
|
| Thyroid hormone signaling pathway |
-1.61 |
3.92e-2 |
112/121 (92.56%) |
MED27;ATP1A1;RCAN2;...
|
| Rap1 signaling pathway |
-1.61 |
3.83e-2 |
184/210 (87.62%) |
MAP2K6;FGFR1;ADCY1;...
|
| Glucagon signaling pathway |
-1.61 |
3.95e-2 |
89/107 (83.18%) |
CALML5;PCK1;PRMT1;...
|
| Axon guidance |
-1.62 |
3.87e-2 |
151/182 (82.97%) |
CDC42;RAC3;PPP3CB;...
|
| Mucin type O-glycan biosynthesis |
-1.64 |
3.60e-2 |
20/36 (55.56%) |
ST3GAL1;GALNT10;GALNT2;...
|
| Glutamatergic synapse |
-1.64 |
3.74e-2 |
97/114 (85.09%) |
PLD1;ADCY1;GNG12;...
|
| Vasopressin-regulated water reabsorption |
-1.64 |
3.77e-2 |
40/44 (90.91%) |
DYNC1H1;ARHGDIB;PRKACB;...
|
| Platelet activation |
-1.64 |
3.89e-2 |
106/124 (85.48%) |
ADCY1;RAP1A;TLN1;...
|
| Gap junction |
-1.66 |
3.56e-2 |
72/88 (81.82%) |
ADCY1;GNAI3;MAPK1;...
|
| Cholinergic synapse |
-1.66 |
3.73e-2 |
99/113 (87.61%) |
JAK2;ADCY1;CHRM3;...
|
| Amphetamine addiction |
-1.66 |
3.86e-2 |
57/69 (82.61%) |
PDYN;CACNA1D;PPP3CB;...
|
| Selenocompound metabolism |
-1.67 |
3.59e-2 |
11/17 (64.71%) |
CTH;MTR;SEPHS1;...
|
| GnRH signaling pathway |
-1.69 |
3.34e-2 |
80/93 (86.02%) |
SOS2;RAF1;ITPR1;...
|
| Aldosterone synthesis and secretion |
-1.69 |
3.48e-2 |
85/98 (86.73%) |
AGTR1;AGT;ITPR1;...
|
| Thyroid hormone synthesis |
-1.69 |
3.64e-2 |
66/75 (88%) |
TTF2;ITPR1;CANX;...
|
| Progesterone-mediated oocyte maturation |
-1.69 |
3.75e-2 |
75/100 (75%) |
CPEB3;STK10;PIK3R1;...
|
| Protein processing in endoplasmic reticulum |
-1.70 |
3.94e-2 |
127/171 (74.27%) |
PDIA4;GANAB;SSR2;...
|
| Circadian entrainment |
-1.71 |
3.86e-2 |
85/97 (87.63%) |
ADCY1;GNG12;CACNA1D;...
|
| Regulation of actin cytoskeleton |
-1.72 |
3.93e-2 |
185/218 (84.86%) |
ITGA1;ARPC2;GNA12;...
|
| Propanoate metabolism |
-1.75 |
3.01e-2 |
30/34 (88.24%) |
MLYCD;BCKDHA;ACOX3;...
|
| Vascular smooth muscle contraction |
-1.75 |
3.11e-2 |
113/133 (84.96%) |
PRKCH;PPP1CB;RAF1;...
|
| Salivary secretion |
-1.78 |
3.34e-2 |
76/93 (81.72%) |
AQP5;ADCY1;CHRM3;...
|
| Gastric acid secretion |
-1.78 |
3.51e-2 |
63/76 (82.89%) |
ADCY1;CCKBR;CHRM3;...
|
| Oocyte meiosis |
-1.78 |
3.87e-2 |
90/129 (69.77%) |
PPP2R5A;ADCY1;PPP3CB;...
|
| Cortisol synthesis and secretion |
-1.81 |
3.51e-2 |
58/65 (89.23%) |
AGTR1;AGT;ITPR1;...
|
| Adherens junction |
-1.86 |
1.81e-2 |
63/71 (88.73%) |
TJP1;SRC;SORBS1;...
|
| Focal adhesion |
-1.87 |
1.76e-2 |
180/201 (89.55%) |
ITGA2;FLNB;TLN2;...
|
| Melanogenesis |
-1.88 |
2.01e-2 |
74/101 (73.27%) |
TCF7L2;LEF1;ADCY1;...
|
| Dopaminergic synapse |
-1.90 |
5.02e-3 |
115/132 (87.12%) |
ITPR1;MAPK9;PPP2R3A;...
|
| Long-term potentiation |
-1.99 |
1.00e-2 |
61/67 (91.04%) |
ADCY1;RAP1A;BRAF;...
|
